Santarus Pharming, Announce New Data from Open-Label Repeat Treatment Study with RUCONEST

By: Benzinga
Santarus (NASDAQ: SNTS ) and Pharming Group NV (OTC: PHGUF ) announced that new data from an open-label extension of the pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.